Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial.
- DOI
- 10.1016/j.jacasi.2025.12.014
- Published
- 2026 May
- Container
- JACC. Asia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jacasi.2025.12.014,
title = {Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial.},
author = {Kan JY and Zhang XJ and Yu WD and Yang ZW and Fan FL and Ding GW and Luo J and Li W and Xie DJ and Liu XF and Zhang H and Chen SL},
year = {2026},
journal = {JACC. Asia},
doi = {10.1016/j.jacasi.2025.12.014},
url = {https://doi.org/10.1016/j.jacasi.2025.12.014}
}RIS
TY - JOUR TI - Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial. AU - Kan JY AU - Zhang XJ AU - Yu WD AU - Yang ZW AU - Fan FL AU - Ding GW AU - Luo J AU - Li W AU - Xie DJ AU - Liu XF AU - Zhang H AU - Chen SL PY - 2026 JO - JACC. Asia DO - 10.1016/j.jacasi.2025.12.014 UR - https://doi.org/10.1016/j.jacasi.2025.12.014 ER -
APA
JY, K., XJ, Z., WD, Y., ZW, Y., FL, F., GW, D., J, L., W, L., DJ, X., XF, L., H, Z., & SL, C. (2026). Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial.. JACC. Asia. https://doi.org/10.1016/j.jacasi.2025.12.014
Source records
- pubmed · retrieved 2026-09-25T19:09:10.512Z